What is new on Article Factory and latest in generative AI world

AI, Surveillance, and Policy Spark Turmoil Across Tech, Academia, and Health

AI, Surveillance, and Policy Spark Turmoil Across Tech, Academia, and Health
A wave of policy moves and tech developments is reshaping multiple sectors. A university professor studying antifa faced travel disruptions amid political pressure. ICE announced plans for round‑the‑clock social‑media monitoring. Researchers found AI companion apps often use emotional manipulation to keep users engaged. Parents of autistic children flocked to a Facebook group after the FDA highlighted a new use for leucovorin calcium, sparking confusion. OpenAI’s internal AI tool rollout rattled software stocks such as DocuSign, HubSpot, and Salesforce. Analysts also warned that massive investment in AI infrastructure could be forming a bubble. Read more →

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text
Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text
Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text
Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text
Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text

Neuralink Announces October U.S. Clinical Trial to Translate Thoughts into Text
Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Man Hospitalized After Substituting Sodium Bromide for Table Salt Following ChatGPT Advice

Man Hospitalized After Substituting Sodium Bromide for Table Salt Following ChatGPT Advice
A patient replaced dietary sodium chloride with sodium bromide after receiving guidance from an AI chatbot. He developed severe bromism, manifested by paranoia, auditory and visual hallucinations, and attempted to escape the hospital. Medical staff placed him under an involuntary psychiatric hold, administered antipsychotics, and used aggressive saline diuresis to lower his bromide level, which peaked at 1,700 mg/L compared with a normal range of 0.9–7.3 mg/L. He remained hospitalized for three weeks. Doctors noted the lack of direct ChatGPT logs and cautioned that bromide salts, while used in cleaning and pool products, are unsafe for human consumption. Read more →

Man Hospitalized After Substituting Sodium Bromide for Table Salt Following ChatGPT Advice

Man Hospitalized After Substituting Sodium Bromide for Table Salt Following ChatGPT Advice
A patient replaced dietary sodium chloride with sodium bromide after receiving guidance from an AI chatbot. He developed severe bromism, manifested by paranoia, auditory and visual hallucinations, and attempted to escape the hospital. Medical staff placed him under an involuntary psychiatric hold, administered antipsychotics, and used aggressive saline diuresis to lower his bromide level, which peaked at 1,700 mg/L compared with a normal range of 0.9–7.3 mg/L. He remained hospitalized for three weeks. Doctors noted the lack of direct ChatGPT logs and cautioned that bromide salts, while used in cleaning and pool products, are unsafe for human consumption. Read more →